Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 16, Issue 2, Pages 118-123
Publisher
Wiley
Online
2013-07-16
DOI
10.1111/dom.12183
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome
- (2014) G. Forlani et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification
- (2013) Andrew Rowland et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
- (2013) Tim Heise et al. Diabetes Therapy
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
- (2011) Muhammad A. Abdul-Ghani et al. ENDOCRINE REVIEWS
- Glucose handling by the kidney
- (2011) Amanda Mather et al. KIDNEY INTERNATIONAL
- Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus
- (2010) Nathalie C. Leite et al. LIVER INTERNATIONAL
- Defining and Characterizing the Progression of Type 2 Diabetes
- (2009) V. A. Fonseca DIABETES CARE
- Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life
- (2009) Michael F. Pollack et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus
- (2009) F. Xavier Pi-Sunyer POSTGRADUATE MEDICINE
- Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management
- (2009) Diego Garcia-Compean et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- (2008) Roger K. Verbeeck EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search